- Newly launched SEIS fund - Focused on investing in seed stage therapeutic and biotech companies.
- Minimum investment amount for investor is £ 10k.
- The geographic scope shall be UK wide but will target the growing Cambridge biotech cluster which is now the global headquarters of AstraZeneca, and is home to many biotech companies some of which have subsequently been snapped up by large pharmaceutical companies.
Fund Size | £ 1.5m |
---|---|
Maximum Subscription | £ 100,000 |
Expected Exit | 3-7 years |
Founder's Investment | Minimum 10% of every investment |
- +History in grassroots science
We have a track record of nurturing and investing in emerging life science and tech companies – the o2h ventures team are leaders in the biotech community and have been involved as investors, holding various board/industry positions awe well as being engaged in grassroot scientific activity for over 20 years.
- +Evaluation
- +Access to scientific talents
- +Business model
SEIS tax relief is very attractive for UK tax payers
You invest £50k
SEIS gives you £25k tax relief from HMRC
SEIS gives you £25k tax relief from HMRC
Investment now worth £100k
£50k profit
income tax relief £25k
performance incentive £10k
net profit £65k
Investment still worth £50k
£0 profit
income tax relief £25k
performance incentive £0
net profit £25k
Investment now worth £0
£50k loss
income tax relief £25k
loss relief £15,750 *
performance incentive £0
capital loss £9,250
* Loss relief calculated on higher rate tax bracket Worked example is net of any fund fees
- o2h ventures – making waves in knowledge intensive and SEIS investing 21 December, 2020
- Knowledge intensive investing… a new investment era 9 December, 2020
- o2h ventures leads the funding into Cambridge University Biotech Spinout Spirea 7 December, 2020